Cardio-oncology is continuous growth area since the advantages obtained from anti-tumor treatments improved the tumor pathology prognosis but, at the same time, increased the mortality and morbidity linked to the cardiovascular side effects of the therapy itself.

Complications include:
  • Arrhythmias
  • Heart failure
  • Ischemic heart disease
  • Valvulopathies
  • Hypertension
  • Thromboembolic diseases
  • Pulmonary hypertension
  • Pericardial complications
  • Peripheral vascular diseases

Generally, the first step is to identify the risk of developing these complications.
The risk factors that expose the patient to the development of cardiovascular complications are:
  • presence of cardiovascular disease risk factors: age > 65, systemic arterial hypertension, dyslipidemia, diabetes mellitus, family history of premature cardiovascular disease (<50 years), smoking, obesity, high alcohol intake, and sedentary habit
  • Current myocardial disease: evidence of coronary artery disease, left ventricular dysfunction, hypertensive heart disease, valvular heart disease
  • Previous cardiotoxic cancer treatment: prior anthracycline use and/or prior chest radiotherapy

Our Cardio-Oncology Team will define a personalized risk-based monitoring protocol that will use the latest medical and bioengineering technologies.

Our aims are:
  • cardiotoxicity prevention
  • early identification and cardiovascular complications treatment of anti-tumor therapy
  • cardiovascular risk factors identification and control
  • allow an optimal anticancer treatment even in patients with increased cardiological risk

Reference: European Heart Journal (2016) 37, 2768–2801

Click here to book a visit in this healthcare area